The MATERNAL SCREEN-2ND TRIMESTER QUADRUPLE test is a prenatal screening test conducted during the second trimester of pregnancy. It assesses the risk of certain chromosomal abnormalities and neural tube defects in the developing fetus.

The MATERNAL SCREEN-2ND TRIMESTER QUADRUPLE test, also known as the Quadruple Marker Screening test, assesses the risk of certain chromosomal abnormalities and neural tube defects in the developing fetus during the second trimester of pregnancy. The test includes the measurement of four specific substances in the maternal blood:

Alpha-fetoprotein (AFP): Elevated AFP levels can suggest a neural tube defect such as spina bifida or anencephaly.

Human Chorionic Gonadotropin (hCG): Abnormal hCG levels may indicate the risk of chromosomal abnormalities, particularly Down syndrome (Trisomy 21).

Estriol: Low estriol levels can be associated with the risk of chromosomal abnormalities.

Inhibin A: Elevated inhibin A levels can also suggest an increased risk of chromosomal abnormalities.

These substances are measured in the maternal blood to provide an assessment of the risk of these conditions in the developing fetus. It's important to note that the MATERNAL SCREEN-2ND TRIMESTER QUADRUPLE test is a screening test, and abnormal results may indicate an increased risk but not a definitive diagnosis. Further diagnostic testing, such as amniocentesis or chorionic villus sampling (CVS), may be recommended if the results are concerning.